製品: B Raf Antibody
カタログ: AF6929
タンパク質の説明: Rabbit polyclonal antibody to B Raf
アプリケーション: ELISA(peptide)
反応性: Human, Mouse
分子量: 84kD(Calculated).
ユニプロット: P15056
RRID: AB_2847719

類似製品を見る>>

   サイズ 価格 在庫状況
 100ul $280 在庫あり
 200ul $350 在庫あり

リードタイム: 当日配達

For pricing and ordering contact:
お問い合わせ先

製品説明

ソース:
Rabbit
アプリケーション:
ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:
Human,Mouse
クローナリティ:
Polyclonal
特異性:
B Raf Antibody detects endogenous levels of total B Raf.
RRID:
AB_2847719
引用形式: Affinity Biosciences Cat# AF6929, RRID:AB_2847719.
コンジュゲート:
Unconjugated.
精製:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
保存:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
別名:

折りたたみ/展開

;FLJ95109; 94 kDa B raf protein; B raf 1; B raf; B Raf proto oncogene serine threonine protein kinase; B Raf proto oncogene, serine/threonine kinase; B RAF1; B-Raf proto-oncogene serine/threonine-protein kinase (p94); BRAF 1; BRAF; BRAF_HUMAN; BRAF1; cRmil; MGC126806; MGC138284; Murine sarcoma viral (v-raf) oncogene homolog B1; Murine sarcoma viral v raf oncogene homolog B1; NS7; Oncogen BRAF; oncogene BRAF1; p94; Proto-oncogene B-Raf; Proto-oncogene c-Rmil; RAFB 1; RAFB1; RMIL; Serine/threonine-protein kinase B-raf; v raf murine sarcoma viral oncogene homolog B; v raf murine sarcoma viral oncogene homolog B1; v-Raf murine sarcoma viral oncogene homolog B1;

免疫原

免疫原:

A synthesized peptide derived from human B Raf.

Uniprot:
遺伝子(ID):
発現特異性:
P15056 BRAF_HUMAN:

Brain and testis.

タンパク質配列:
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH

PTMs - P15056 基板として

Site PTM Type Enzyme
S76 Phosphorylation
T119 Phosphorylation
S147 Phosphorylation P15056 (BRAF)
S151 Phosphorylation P28482 (MAPK1) , P15056 (BRAF) , P27361 (MAPK3)
K164 Ubiquitination
T244 Phosphorylation
K253 Acetylation
K253 Ubiquitination
S314 Phosphorylation
S316 Phosphorylation
S317 Phosphorylation
S319 Phosphorylation
S333 Phosphorylation
S335 Phosphorylation
S339 Phosphorylation
S363 Phosphorylation
S364 Phosphorylation P31751 (AKT2) , Q9Y243 (AKT3) , O00141 (SGK1)
S365 Phosphorylation O00141 (SGK1) , P31749 (AKT1) , Q9Y243 (AKT3)
T373 Phosphorylation P15056 (BRAF)
S394 Phosphorylation
T396 Phosphorylation
S399 Phosphorylation
T401 Phosphorylation P28482 (MAPK1) , P27361 (MAPK3)
S405 Phosphorylation
K418 Acetylation
S419 Phosphorylation P15056 (BRAF)
S428 Phosphorylation Q9Y243 (AKT3) , P31751 (AKT2)
S429 Phosphorylation Q9Y243 (AKT3) , P31749 (AKT1)
S430 Phosphorylation P17612 (PRKACA)
S431 Phosphorylation
S432 Phosphorylation
T440 Phosphorylation P31751 (AKT2)
S445 Phosphorylation
S446 Phosphorylation Q13153 (PAK1) , Q15382 (RHEB)
S447 Phosphorylation
T458 Phosphorylation
S465 Phosphorylation
S467 Phosphorylation
T470 Phosphorylation
K473 Ubiquitination
K475 Ubiquitination
Y566 Phosphorylation
K578 Ubiquitination
S579 Phosphorylation
T599 Phosphorylation
K601 Ubiquitination
S602 Phosphorylation
S605 Phosphorylation
S614 Phosphorylation P15056 (BRAF)
R671 Methylation
S675 Phosphorylation
K687 Ubiquitination
S727 Phosphorylation
S729 Phosphorylation Q13131 (PRKAA1)
S732 Phosphorylation
Y746 Phosphorylation
S750 Phosphorylation P28482 (MAPK1) , P15056 (BRAF)
T753 Phosphorylation P28482 (MAPK1) , P27361 (MAPK3)
Y760 Phosphorylation

PTMs - P15056 酵素として

Substrate Site Source
P15056 (BRAF) S147 Uniprot
P15056 (BRAF) S151 Uniprot
P15056 (BRAF) T373 Uniprot
P15056 (BRAF) S419 Uniprot
P15056 (BRAF) S614 Uniprot
P15056 (BRAF) S750 Uniprot
P33981 (TTK) S281 Uniprot
P33981 (TTK) S436 Uniprot
P36507 (MAP2K2) S222 Uniprot
P36507 (MAP2K2) S226 Uniprot
P68104 (EEF1A1) S21 Uniprot
P68104 (EEF1A1) T88 Uniprot
Q02750 (MAP2K1) S218 Uniprot
Q02750-1 (MAP2K1) S222 Uniprot
Q05639 (EEF1A2) S21 Uniprot
Q92934 (BAD) S75 Uniprot
Q92934 (BAD) S99 Uniprot
Q92934 (BAD) S118 Uniprot
Q92934 (BAD) S134 Uniprot

研究背景

機能:

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway. May play a role in the postsynaptic responses of hippocampal neurons.

PTMs:

Phosphorylation at Ser-365 by SGK1 inhibits its activity.

Methylation at Arg-671 decreases stability and kinase activity.

Ubiquitinated by RNF149; which leads to proteasomal degradation. Polyubiquitinated at Lys-578 in response to EGF.

細胞の位置付け:

Nucleus. Cytoplasm. Cell membrane.
Note: Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
組織特異性:

Brain and testis.

サブユニット構造:

Monomer. Homodimer. Heterodimerizes with RAF1, and the heterodimer possesses a highly increased kinase activity compared to the respective homodimers or monomers. Heterodimerization is mitogen-regulated and enhanced by 14-3-3 proteins. MAPK1/ERK2 activation can induce a negative feedback that promotes the dissociation of the heterodimer by phosphorylating BRAF at Thr-753. Heterodimerizes (via N-terminus) with KSR1 (via N-terminus) or KSR2 (via N-terminus) in a MAP2K1-dependent manner. Interacts with MAP2K1 and MAP2K2. Found in a complex with at least BRAF, HRAS, MAP2K1, MAPK3 and RGS14. Interacts with RIT1. Interacts (via N-terminus) with RGS14 (via RBD domains); the interaction mediates the formation of a ternary complex with RAF1, a ternary complex inhibited by GNAI1 (By similarity). Interacts with DGKH. Interacts with PRMT5. Interacts with KSR2. Interacts with AKAP13, MAP2K1 and KSR1. Identified in a complex with AKAP13, MAP2K1 and KSR1. Interacts with FNIP1 and FNIP2.

タンパク質ファミリー:

Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.

研究領域

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion.   (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway.   (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Substance dependence > Alcoholism.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Glioma.   (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Thyroid cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Bladder cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway.   (View pathway)

· Organismal Systems > Circulatory system > Vascular smooth muscle contraction.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Nervous system > Long-term potentiation.

· Organismal Systems > Nervous system > Neurotrophin signaling pathway.   (View pathway)

· Organismal Systems > Nervous system > Serotonergic synapse.

· Organismal Systems > Nervous system > Long-term depression.

· Organismal Systems > Endocrine system > Insulin signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.